Status:
RECRUITING
Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation
Lead Sponsor:
Rennes University Hospital
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Liver Transplantation
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate ...
Eligibility Criteria
Inclusion
- Male and female subjects equal or above 18 yrs old.
- Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
- Capability of understanding the purpose and risks of the study.
- Written informed consent
Exclusion
- Fulminant hepatitis
- Kidney injury at baseline (Estimated Glomerular Filtration Rate \< 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
- Use of an induction agent Basiliximab at liver transplantation
- Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty
- At the time of randomisation, participation to another interventional study
Key Trial Info
Start Date :
March 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 26 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06535945
Start Date
March 26 2025
End Date
April 26 2028
Last Update
December 9 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
08_CHRU de Tours Hôpital Trousseau
Chambray-lès-Tours, France, 37170
2
03_APHP Hôpital Beaujon
Clichy, France, 92110
3
04_CHU de Lille Hôpital Huriez
Lille, France, 59000
4
05_HCL Hôpital de la Croix Rousse
Lyon, France, 69004